Genentech Wins FDA Priority Review for Enspryng in Thyroid Eye Disease
SOUTH SAN FRANCISCO, Calif., June 29, 2026 Genentech, a member of the Roche Group, announced that the U.S. Food...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., June 29, 2026 Genentech, a member of the Roche Group, announced that the U.S. Food...
BASEL, Switzerland, April 2026 Roche reported new clinical findings demonstrating the effectiveness of ENSPRYNG® (satralizumab) in reducing relapse risk...
